HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy

Cancer Gene Therapy

Volumn 20, Issue 8, 2013, Pages 478-485

  Li, H ^a   Nakashima, H ^b   Decklever, T D ^a   Nace, R A ^a   Russell, S J ^a  

^a MAYO CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

gene therapy; herpesvirus; prostatic neoplasms; radiotherapy; sodium iodide symporter

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE 131; ONCOLYTIC HERPES SIMPLEX VIRUS TYPE1 SODIUM IODIDE SYMPORTER; ONCOLYTIC HERPES VIRUS; PERTECHNETIC ACID TC 99M; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL STRAIN LNCAP; CONTROLLED STUDY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR XENOGRAFT; VIRUS GENOME; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MUS; MUS MUSCULUS; SIMPLEXVIRUS;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENETIC THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SYMPORTERS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882454089     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.43     Document Type: Article

References (50)

1. ACS. Cancer facts and figures 2012 http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
2. D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 2012; 13: 189-195.
3. Fukuhara H, Homma Y, Todo T. Oncolytic virus therapy for prostate cancer. Int J Urol 2010; 17: 20-30.
4. Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16: 1761-1769.
5. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011; 21: 213-226.
6. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6: 941-949.
7. Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21: 1119-1128.
8. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-4015.
9. Russell SJ, Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther 2008; 10: 380-386.
10. Todo T. Active immunotherapy oncolytic virus therapy using HSV-1. Adv Exp Med Biol 2012; 746: 178-186.
11. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 2012; 20: 287-297.
12. Lee CY, Bu LX, DeBenedetti A, Williams BJ, Rennie PS, Jia WW. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther 2010; 18: 929-935.
13. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012; 72: 1621-1631.
14. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17: 614-622.
15. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104: 12879-12883.
16. Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 2012; 20: 221-229.
17. Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD et al. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 2011; 17: 7383-7393.
18. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158-6166.
19. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008; 10: 362-370.
20. Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: principles and prospects in oncology. Curr Pharm Des 2012; 18: 3313-3320.
21. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Imageguided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
22. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Therapy 2011; 19: 279-287.
23. Penheiter AR, Wegman TR, Classic KL, Dingli D, Bender CE, Russell SJ et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. Am J Roentgenol 2010; 195: 341-349.
24. Rajecki M, Kangasmaki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J et al. Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Delta24-hNIS. Mol Ther 2011; 19: 629-631.
25. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Therapy 2012; 19: 279-287.
26. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther 2012; 23: 295-301.
27. Gholami S, Haddad D, Chen CH, Chen NG, Zhang Q, Zanzonico PB et al. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery 2011; 150: 1040-1047.
28. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17: 550-558.
29. Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA et al. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res 2009; 15: 5396-5403.
30. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110: 2342-2350.
31. Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther 2012; 23: 419-427.
32. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Therapy 2006; 13: 705-714.
33. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65: 2832-2839.
34. Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L et al. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med 2011; 9: 36.
35. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17: 2041-2048.
36. Naik S, Nace R, Barber GN, Russell SJ. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther 2012; 19: 443-450.
37. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 2012; 26: 1870-1878.
38. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010; 18: 285-294.
39. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007; 67: 9371-9379.
40. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496-509.
41. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
42. Dingli D, Cascino MD, Josic K, Russell SJ, Bajzer Z. Mathematical modeling of cancer radiovirotherapy. Math Biosci 2006; 199: 55-78.
43. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82: 700-710.
44. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 2005; 12: 437-445.
45. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.
46. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S et al. Adenovirusmediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
47. Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, Zhang Y et al. Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 2011; 19: 1353-1359.
48. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516-10520.
49. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
50. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874.